SEATTLE, July 06, 2021, (MEDGADGET) — Global Fc Protein and Glycoengineered Antibodies Market Analysis
Overview
Monoclonal antibodies are therapeutic antibodies generated by similar immune cells. Succeeding antibodies have crystallized fragments (Fc) protein and glycoengineered antibodies. These monoclonal antibodies are glycoprotein G (IgG) molecules with a glycan residue bound to a crystalline portion. Glycoengineering is the process of making these antibodies. They are used to treat illnesses like rheumatoid arthritis and tumors in a variety of ways.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/2626
Drivers
The global Fc protein and glycoengineered antibodies market is projected to expand at a faster rate than the overall market over the forecast period, attributable to main players concentrating on research and development and gaining regulatory approvals.
The U.S. Food and Drug Administration (FDA) granted Genentech Inc. approval for Tecentriq in 2016. It is a drug used to cure urothelial carcinoma. Tecentriq obtained its second FDA approval for the treatment of small lung cancer in March 2019. TG Therapeutics, Inc. has started a clinical trial of Ublituximab for the treatment of multiple sclerosis in November 2017. The clinical trial is now in its third phase. The global fc protein and glycoengineered antibodies market is expected to expand due to factors such as rising product approvals and a strong pipeline.
The global Fc protein and glycoengineered antibodies market is projected to rise due to the growing occurrence of chronic diseases. As per the World Health Organization (WHO), cancer is the second leading cause of death globally, with almost 9.6 million people dying from cancer in 2018. As a result, glycoengineered antibodies can be produced for cancer care, and this trend is expected to propel the global fc protein and glycoengineered antibodies market forward in the near future.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2626
Restraints
The global Fc protein and glycoengineered antibodies market is expected to be hampered by high medication costs. Manufacturers are concentrating their efforts on providing a highly successful medicine, so they are spending more in research and development. As a result, the product’s final cost rises. Gazyva costs about US$ 41,300 for a six-month treatment, as per Pharmacy and Healthcare Communication, LLC. Thus, the global Fc protein and glycoengineered antibodies market is estimated to be restrained by this aspect.
Regional Insights
Due to product releases, the participation of leading manufacturers and successful research and development in the region, the North America is projected to dominate the global fc protein and glycoengineered antibodies market. In the U.S., drugs like Imfinzi (Durvalumab), Tecentriq (Atezolizumab), Gazyva (Obinutuzumab), and Poteligeo (Mogamulizumab) were approved in 2013, 2016, and 2017.
The global Fc protein and glycoengineered antibodies market is expected to expand significantly in Europe. Over the forecast period, factors such as new drug approval are projected to drive the development of Europe’s Fc protein and glycoengineered antibodies market. The European Commission granted Kyowa Hakko Kirin Co. Ltd. permission to sell the Poteligeo antibody in Europe in 2018. It is the first biological agent to target the chemokine receptor 4 (CCR4), and it’ll be used to combat Sezary syndrome, which has traditionally been treated with systemic therapy. Over the forecast period, new drug approvals are anticipated to drive Europe’s Fc protein and glycoengineered antibodies market development.
To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/2626
Key Players
Key companies contributing in the global Fc protein and glycoengineered antibodies market are Boehringer Ingelheim International GmbH, Genentech Inc., Celldex Therapeutics, Kyowa Hakko Kirin Co. Ltd., Amgen Inc., TG Therapeutics, Inc., Merck KGaA, Clovis Oncology, Five Prime Therapeutics Inc., and AstraZeneca Plc.
Table of Content
Global Fc Protein and Glycoengineered Antibodies Market Research Report
Section 1: Global Fc Protein and Glycoengineered Antibodies Industry Overview
Section 2: Global Economic Impact on Fc Protein and Glycoengineered Antibodies Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Fc Protein and Glycoengineered Antibodies Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Fc Protein and Glycoengineered Antibodies Market Forecast
Other Related Reports:
WEIGHT MANAGEMENT MARKET ANALYSIS
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET ANALYSIS
TARGETED CANCER THERAPIES MARKET ANALYSIS
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837